Aleena Banerji
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Aleena Banerji has a total of 81 co-authors. Here are the top co-authors by number of shared publications:
- Carlos Arturo Camargo
Department of Emergency Medicine, Massachusetts General Hospital, Boston, MA, United States
8 shared publications Kimberly G. Blumenthal
Edward P. Lawrence Center for Quality and Safety, Massachusetts General Hospital, Boston, Massachusetts; Division of Rheumatology, Allergy and Immunology, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts; Harvard Medical School, Boston, Massachusetts
4 shared publicationsSunday Clark
Department of Emergency Medicine, Weill Cornell Medical College, New York, NY
4 shared publicationsAidan A. Long
Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Mass
3 shared publicationsAutumn Guyer
Division of Pulmonary, Critical Care, Allergy, and Sleep Medicine, University of California San Francisco, San Francisco, CA
3 shared publicationsJonathan A. Bernstein
3 shared publications
Latest Publications
- 1 June 2021
- Published by Elsevier in Annals of Allergy, Asthma & Immunology
- Vol. 126 (6) , 739-741
Drug desensitization in the coronavirus disease 2019 pandemic era
- 1 June 2021
- Published by Elsevier in Annals of Allergy, Asthma & Immunology
- Vol. 126 (6) , 739-741
Drug desensitization in the coronavirus disease 2019 pandemic era
- 1 May 2021
- Published by Elsevier in The Journal of Allergy and Clinical Immunology: In Practice
- Vol. 9 (5) , 1980-1991
Perioperative Allergic Reactions: Allergy Assessment and Subsequent Anesthesia
- 1 May 2021
- Published by Elsevier in The Journal of Allergy and Clinical Immunology: In Practice
- Vol. 9 (5) , 1980-1991
Perioperative Allergic Reactions: Allergy Assessment and Subsequent Anesthesia
- 1 March 2020
- Published by Elsevier in The Journal of Allergy and Clinical Immunology: In Practice
- Vol. 8 (3) , 1032-1038.e1
Natural Language Processing Combined with ICD-9-CM Codes as a Novel Method to Study the Epidemiology of Allergic Drug Reactions
- 1 March 2020
- Published by Elsevier in The Journal of Allergy and Clinical Immunology: In Practice
- Vol. 8 (3) , 1032-1038.e1
Natural Language Processing Combined with ICD-9-CM Codes as a Novel Method to Study the Epidemiology of Allergic Drug Reactions
- 1 May 2017
- Published by Elsevier in The Journal of Allergy and Clinical Immunology: In Practice
- Vol. 5 (3) , 744-749
Epidemiology of ACE Inhibitor Angioedema Utilizing a Large Electronic Health Record
- 1 May 2017
- Published by Elsevier in The Journal of Allergy and Clinical Immunology: In Practice
- Vol. 5 (3) , 744-749
Epidemiology of ACE Inhibitor Angioedema Utilizing a Large Electronic Health Record
- 23 February 2017
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 376 (8) , 717-728
Inhibiting Plasma Kallikrein for Hereditary Angioedema Prophylaxis
Hereditary angioedema with C1 inhibitor deficiency is characterized by recurrent, unpredictable swelling episodes caused by uncontrolled plasma kallikrein generation and excessive bradykinin release resulting from cleavage of high-molecular-weight kininogen. Lanadelumab (DX-2930) is a new kallikrein inhibitor with the potential for prophylactic treatment of hereditary angioedema with C1 inhibitor deficiency.
- 23 February 2017
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 376 (8) , 717-728
Inhibiting Plasma Kallikrein for Hereditary Angioedema Prophylaxis
Hereditary angioedema with C1 inhibitor deficiency is characterized by recurrent, unpredictable swelling episodes caused by uncontrolled plasma kallikrein generation and excessive bradykinin release resulting from cleavage of high-molecular-weight kininogen. Lanadelumab (DX-2930) is a new kallikrein inhibitor with the potential for prophylactic treatment of hereditary angioedema with C1 inhibitor deficiency.
- Open Access
- 15 March 2016
- Published by SAGE Publications in Women's Health
- Vol. 12 (3) , 351-361
Managing the Female Patient with Hereditary Angioedema
Hereditary angioedema (HAE) is a rare disorder resulting from decreased functional levels of C1 -inhibitor (C1-INH), which manifests as periodic episodes of localized edema which can be extremely painful, debilitating and even fatal if the swelling affects the larynx. HAE can complicate many aspects of obstetric/gynecologic care, and an awareness of the disease is critical for clinicians involved in the care of women because of potential HAE-related complications pertaining to pregnancy, labor and delivery, and other women's health issues. This article provides a review of published literature specific to HAE and its management in female patients, including important concerns regarding obstetric/gynecologic care. A growing body of relevant experience is presented to help guide the care of women with HAE.
- 15 March 2016
- Published by SAGE Publications in Women's Health
- Vol. 12 (3) , 351-361
Open AccessManaging the Female Patient with Hereditary Angioedema
Hereditary angioedema (HAE) is a rare disorder resulting from decreased functional levels of C1 -inhibitor (C1-INH), which manifests as periodic episodes of localized edema which can be extremely painful, debilitating and even fatal if the swelling affects the larynx. HAE can complicate many aspects of obstetric/gynecologic care, and an awareness of the disease is critical for clinicians involved in the care of women because of potential HAE-related complications pertaining to pregnancy, labor and delivery, and other women's health issues. This article provides a review of published literature specific to HAE and its management in female patients, including important concerns regarding obstetric/gynecologic care. A growing body of relevant experience is presented to help guide the care of women with HAE.
- Open Access
- 1 January 2016
- Published by SAGE Publications in Allergy & Rhinology
- Vol. 7 (3) , 172-181
Expert Perspectives on Hereditary Angioedema: Key Areas for Advancements in Care across the Patient Journey
Background: Published literature documents the substantial burden of hereditary angioedema (HAE) with C1 inhibitor deficiency on the quality of life and work productivity of patients. However, despite advances in the field and the availability of guidelines to advise health care providers (HCP) on the diagnosis and management of HAE, there are still many challenges to overcome. For example, delayed diagnosis and misdiagnosis are common, and treatment practices vary worldwide. Objective: An international expert panel was convened to consider opportunities for improvements that would benefit patients with HAE. Methods: Based on professional and personal experiences, the experts developed schematics to describe the journey of patients through the following stages: (1) onset of symptoms and initial evaluation; (2) referral/diagnosis; and (3) management of HAE. More importantly, the panel identified key areas in which it was possible to optimize the support provided to patients and HCPs along this journey. Results: Overall, this approach highlighted the need for wider dissemination of algorithms and scientific data to more effectively educate HCPs from multiple disciplines and the need for more research to inform appropriate treatment decisions. Furthermore, HAE awareness campaigns, accurate online information, and referral to patient advocacy groups were all considered helpful approaches to support patients. Conclusion: More detailed and widespread information on the diagnosis and management of HAE is needed and may lead to advancements in care throughout the journey of the patient with HAE.
- 1 January 2016
- Published by SAGE Publications in Allergy & Rhinology
- Vol. 7 (3) , 172-181
Open AccessExpert Perspectives on Hereditary Angioedema: Key Areas for Advancements in Care across the Patient Journey
Background: Published literature documents the substantial burden of hereditary angioedema (HAE) with C1 inhibitor deficiency on the quality of life and work productivity of patients. However, despite advances in the field and the availability of guidelines to advise health care providers (HCP) on the diagnosis and management of HAE, there are still many challenges to overcome. For example, delayed diagnosis and misdiagnosis are common, and treatment practices vary worldwide. Objective: An international expert panel was convened to consider opportunities for improvements that would benefit patients with HAE. Methods: Based on professional and personal experiences, the experts developed schematics to describe the journey of patients through the following stages: (1) onset of symptoms and initial evaluation; (2) referral/diagnosis; and (3) management of HAE. More importantly, the panel identified key areas in which it was possible to optimize the support provided to patients and HCPs along this journey. Results: Overall, this approach highlighted the need for wider dissemination of algorithms and scientific data to more effectively educate HCPs from multiple disciplines and the need for more research to inform appropriate treatment decisions. Furthermore, HAE awareness campaigns, accurate online information, and referral to patient advocacy groups were all considered helpful approaches to support patients. Conclusion: More detailed and widespread information on the diagnosis and management of HAE is needed and may lead to advancements in care throughout the journey of the patient with HAE.
- 1 May 2015
- Published by Oceanside Publications Inc. in Allergy and Asthma Proceedings
- Vol. 36 (3) , 213-217
Current state of hereditary angioedema management: A patient survey
Hereditary angioedema (HAE) is a chronic disease with a high burden of disease that is poorly understood and often misdiagnosed. Availability of treatments, including C1 esterase inhibitor (C1INH) replacement, ecallantide, and icatibant, marks a significant advance for HAE patients. We aimed to better understand the current state of HAE care, from a patient perspective, after the introduction of several novel therapies. One session of the United States Hereditary Angioedema Association 2013 patient summit was devoted to data collection for this study. Patients attending the summit were self-selected, and HAE diagnosis was self-reported. Survey questions assessed patient characteristics, burden of disease, and treatment. Participant responses were captured using an audience response system. We surveyed 149 (80%) type I and II HAE (HAE-C1INH) and 37 (20%) HAE with normal C1INH (HAE-nlC1INH) patients. HAE-C1INH (72%) and HAE-nlCINH patients (76%) equally reported that HAE had a significant impact on quality of life (QOL). A third of HAE-C1INH patients were diagnosed within one year of their first HAE attack, but another third reported a delay of more than 10 years. Most HAE-C1INH (88%) and HAE-nlC1INH (76%) patients had on-demand treatment available. HAE-C1INH patients frequently had an individual treatment plan (76%) compared with 50% of HAE-nlC1INH patients. Most HAE-C1INH patients went to the emergency department (ED) or were hospitalized less than once every six months (80%). Our findings show that HAE management is improving with good access to on-demand and prophylactic treatment options. However, HAE patients still have a significant burden of disease and continued research and educational efforts are needed.
- 1 May 2015
- Published by Oceanside Publications Inc. in Allergy and Asthma Proceedings
- Vol. 36 (3) , 213-217
Current state of hereditary angioedema management: A patient survey
Hereditary angioedema (HAE) is a chronic disease with a high burden of disease that is poorly understood and often misdiagnosed. Availability of treatments, including C1 esterase inhibitor (C1INH) replacement, ecallantide, and icatibant, marks a significant advance for HAE patients. We aimed to better understand the current state of HAE care, from a patient perspective, after the introduction of several novel therapies. One session of the United States Hereditary Angioedema Association 2013 patient summit was devoted to data collection for this study. Patients attending the summit were self-selected, and HAE diagnosis was self-reported. Survey questions assessed patient characteristics, burden of disease, and treatment. Participant responses were captured using an audience response system. We surveyed 149 (80%) type I and II HAE (HAE-C1INH) and 37 (20%) HAE with normal C1INH (HAE-nlC1INH) patients. HAE-C1INH (72%) and HAE-nlCINH patients (76%) equally reported that HAE had a significant impact on quality of life (QOL). A third of HAE-C1INH patients were diagnosed within one year of their first HAE attack, but another third reported a delay of more than 10 years. Most HAE-C1INH (88%) and HAE-nlC1INH (76%) patients had on-demand treatment available. HAE-C1INH patients frequently had an individual treatment plan (76%) compared with 50% of HAE-nlC1INH patients. Most HAE-C1INH patients went to the emergency department (ED) or were hospitalized less than once every six months (80%). Our findings show that HAE management is improving with good access to on-demand and prophylactic treatment options. However, HAE patients still have a significant burden of disease and continued research and educational efforts are needed.
- 1 July 2014
- Published by Elsevier in The Journal of Allergy and Clinical Immunology: In Practice
- Vol. 2 (4) , 428-433
Management of Hypersensitivity Reactions to Carboplatin and Paclitaxel in an Outpatient Oncology Infusion Center: A 5-Year Review
- 1 July 2014
- Published by Elsevier in The Journal of Allergy and Clinical Immunology: In Practice
- Vol. 2 (4) , 428-433
Management of Hypersensitivity Reactions to Carboplatin and Paclitaxel in an Outpatient Oncology Infusion Center: A 5-Year Review